Improvement and Application of New Closed Drainage Device (IAAONCDD)
Improvement and Clinical Application of a New Minimally Invasive Closed Thoracic Drainage System
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Wenli Wang, Master's degree
- Phone Number: +86021661110 13761295864
- Email: Anderson840913@163.com
Study Contact Backup
- Name: Yongxin zhou
- Phone Number: 8602166111070 13681666828
- Email: zhou6302@tongji.edu.cn
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
The selection criteria were as follows:
- age 18-70 years, gender is not limited;
- subjects clearly understand the purpose of the study, are willing and able to comply with the requirements to complete the study and sign the informed consent;
- 18 Kg/m2 < BMI < 25 Kg/m2;
- patients who need thoracic closed drainage for exhaust and drainage because of pneumothorax volume > 30%;
- subjects did not have serious chest wall deformities.
Exclusion criteria:
- Patients at high risk of bleeding, including patients with congenital hemophilia, thrombocytopenia (PLT < 50 *109/L), platelet dysfunction (such as idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet dysfunction);
- Cardiopulmonary function is poor, which is not suitable for the participants.
- Patients with other infectious diseases (inflammation, tuberculosis) or empyema in the thoracic cavity;
- Infection of skin around puncture and drainage;
- Participated in other clinical trials within 30 days;
- Other reasons why the researchers think it is inappropriate to participate in the experiment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: New Closed Drainage Device
We further improve the new closed thoracic drainage system by changing the material of drainage tube, adding external fixator control valve and increasing the gas flow monitoring kit for special patients, and apply it in clinical practice.
|
For the first group, a new closed drainage device was adopted.
|
|
EXPERIMENTAL: Traditional Closed Drainage Device
We use traditional closed drainage devices for patients with hemothorax and pneumothorax.
|
For group 2, conventional closed drainage device was used.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total drainage time
Time Frame: up to 24 weeks
|
Efficiency of treatment
|
up to 24 weeks
|
|
Pulmonary reexpansion ratio
Time Frame: up to 24 weeks
|
Pulmonary reexpansion ratio
|
up to 24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
VAS pain score during and after operation
Time Frame: up to 24 weeks
|
0 points means no pain; 1 points - 3 points means mild pain that patients can tolerate; 4 points - 6 points means pain affect sleep, but patients can tolerate;7 points - 10 points: means patients have gradually strong pain, which have affected appetite and sleep.
|
up to 24 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Operation time of thoracentesis
Time Frame: up to 24 hours
|
Operation time of thoracentesis
|
up to 24 hours
|
|
Percentage of lung recruitment on day 1 and 3
Time Frame: up to 24 weeks
|
Percentage of lung recruitment
|
up to 24 weeks
|
|
Operational-related complications
Time Frame: up to 24 weeks
|
Incidence of loss of thoracic wall nerves, intercostal vessels and thoracic and abdominal organs
|
up to 24 weeks
|
|
Incidence of related accidents after catheterization
Time Frame: up to 24 weeks
|
Incidence rate of peri-drainage tube exudation, drainage tube falling off, drainage tube obstruction and subcutaneous emphysema
|
up to 24 weeks
|
|
The size of the wound
Time Frame: up to 24 weeks
|
The size of the wound
|
up to 24 weeks
|
|
infection of the wound
Time Frame: up to 24 weeks
|
infection of the wound
|
up to 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Wang WP, Ni YF, Wei YN, Li XF, Cheng QS, Lu Q. Bronchiolitis obliterans complicating a pneumothorax after Stevens-Johnson syndrome induced by lamotrigine. J Formos Med Assoc. 2015 Mar;114(3):285-9. doi: 10.1016/j.jfma.2012.02.026. Epub 2012 Jun 6.
- Khan BA, Reddy PM, Khan AM. Spontaneous pneumothorax in the immediate post-operative hour in a primigravida following emergency caesarean section under spinal anaesthesia. Indian J Anaesth. 2015 Feb;59(2):126-9. doi: 10.4103/0019-5049.151380. No abstract available.
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018-LCYJ-012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.